| Jan. 7, 2025 | PostEra × Pfizer PFE.N | $610 mln potential; incl. $12 mln upfront | Expand Pfizer–PostEra AI Lab and add ADC payload-design program |
| Jan. 13, 2025 | IQVIA IQV.N × NVIDIA NVDA.O | Undisclosed | Build custom AI models/agents to automate R&D-commercial workflows |
| Feb. 20, 2025 | Incyte INCY.O × Genesis Therapeutics | $30 mln upfront; up to $295 mln/target milestones + royalties | Use GEMS platform to design small molecules for Incyte targets |
| Mar. 3, 2025 | Kyndryl KD.N × Microsoft MSFT.O | Undisclosed | Deploy Dragon Copilot to reduce documentation burden |
| Mar. 18, 2025 | GE HealthCare GEHC.O × NVIDIA | Undisclosed | Develop autonomous X-ray and ultrasound workflows |
| Mar. 25, 2025 | Cleveland Clinic × G42 | Undisclosed | Form task force to accelerate AI use in care and operations |
| Apr. 16, 2025 | Kenvue KVUE.N × Microsoft | Undisclosed (5-yr) | Modernize operations using Azure, genAI, and digital twins |
| Apr. 29, 2025 | Eli Lilly LLY.N × Creyon Bio | $13 mln upfront; >$1 bln milestones | Use AI engine to design improved RNA-targeted oligos |
| May 21, 2025 | Genentech (Roche) ROG.S × Orionis Biosciences | $105 mln upfront; >$2 bln milestones + royalties | Discover monovalent molecular glues using Allo-Glue platform |
| Jun. 11, 2025 | Novo Nordisk NOVOb.CO × NVIDIA × DCAI (Gefion) | Undisclosed | Build bespoke AI models using Gefion supercomputer |
| Jun. 13, 2025 | AstraZeneca AZN.L × CSPC Pharmaceutical 1093.HK | $110 mln upfront; up to $1.62 bln dev milestones; up to $3.6 bln sales milestones | Discover oral drug candidates; AZ holds global licensing rights |
| Jun. 29-30, 2025 | Pfizer × XtalPi 2228.HK | Undisclosed | Expand to next-gen physics + AI modelling platform |
| Jul. 2, 2025 | AstraZeneca × Modella AI | Undisclosed (multi-year) | Use multimodal AI models to speed oncology development |
| Aug. 14, 2025 | Eli Lilly × Superluminal Medicines | Up to $1.3 bln + royalties | Apply AI GPCR platform to undisclosed targets |
| Sep. 1, 2025 | University of Oxford × Ellison Institute | £118 mln funding | Use AI + challenge models to map correlates of immunity |
| Sep. 23, 2025 | Merck KGaA MRCG.DE × Siemens SIEGn.DE | Undisclosed (MoU) | Connect R&D and manufacturing through Siemens digital platforms |
| Oct. 14, 2025 | Takeda 4502.T × Nabla Bio | Double-digit millions upfront + >$1 bln milestones | Use JAM AI model to design antibodies and multispecifics |
| Oct. 26-27, 2025 | Novartis NOVN.S × Avidity Biosciences RNA.O | ~$12 bln cash | Acquire Avidity to strengthen xRNA and neuromuscular portfolio |
| Oct. 28, 2025 | Eli Lilly × NVIDIA | Undisclosed (>1,000 GPUs) | Build large-scale AI supercomputer for R&D |
| Oct. 28, 2025 | Johnson & Johnson MedTech JNJ.N × NVIDIA | Undisclosed | Use Isaac + Omniverse to simulate OR workflows |
| Nov. 10, 2025 | Eli Lilly × Insilico Medicine | >$100 mln potential + royalties | Use Pharma.AI to design small-molecule candidates |
| Nov. 20, 2025 | Merck KGaA × Valo Health | Over $3 bln potential | Use Valo’s human-data AI to identify targets and speed preclinical work |
| Dec. 9, 2025 | Novartis × Relation Therapeutics | $55 mln upfront + up to $1.7 bln milestones | Use AI + multi-omics to find first-in-class targets |
| Jan. 7, 2026 | GSK GSK.L × Helix | Undisclosed | Provide GSK exome + longitudinal data for target discovery |
| Jan. 8, 2026 | GSK × Noetik | $50 mln upfront + near-term milestones | License AI virtual-cell models for cancer research |
| Jan. 8, 2026 | Pfizer × Boltz | Undisclosed | Fine-tune Boltz AI models with Pfizer data |
| Jan. 9, 2026 | Schrodinger SDGR.O × Eli Lilly | Undisclosed | Integrate TuneLab models into LiveDesign |
| Jan. 12, 2026 | NVIDIA × Thermo Fisher TMO.N | Undisclosed | Pair NVIDIA AI with lab instruments for automation |
| Jan. 12, 2026 | NVIDIA × Eli Lilly | Up to $1 bln over 5 years | Create closed-loop AI + robotics discovery lab |
| Jan. 13, 2026 | Illumina ILMN.O × AstraZeneca × Merck MRK.N × Eli Lilly | Undisclosed | Launch Billion Cell Atlas for large-scale AI training |
| Jan. 13, 2026 | AstraZeneca acquires Modella AI | Undisclosed | Acquire Modella to deploy foundation models across oncology R&D |
| Apr. 14, 2026 | Novo Nordisk NOVOb.CO × OpenAI | Undisclosed | Deploy AI across business, from drug discovery to manufacturing and commercial operations |
| Apr. 14, 2026 | Labcorp LH.N × Amazon Web Services × Datavant | Undisclosed | New AI-powered real-world data platform to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster |
| Apr. 14, 2026 | Vasa Therapeutics × Eli Lilly | Undisclosed | Use Lilly TuneLab, an AI-enabled drug discovery platform trained on Lilly's proprietary data |
| Apr. 22, 2026 | Merck × Alphabet's Google Cloud | $1 billion | Build AI capabilities, including infrastructure, engineers and licensing of Gemini Enterprise |
| Apr. 28, 2026 | Profluent × Eli Lilly | Upfront payment + up to $2.25 billion in milestones and royalties | Research collaboration to develop and commercialize custom site-specific recombinases |
| May 6, 2026 | Simulations Plus SLP.O × NVIDIA | Undisclosed | Technical collaboration focused on GPU-accelerated simulation and AI-assisted workflows |
| May 7, 2026 | Roche × PathAI | $750 million upfront + up to $300 million in milestones | Strengthen Roche's position in digital pathology and automate manual workflows |
| May 13, 2026 | Owkin × AstraZeneca | Undisclosed | Build biopharma agents as part of a three-year licensing of K Pro, Owkin’s AI Scientist for biopharma decision making |
| May 13, 2026 | IQVIA × Kexing Biopharm 688136.SS | Undisclosed | Support a global, multi-product biosimilar development and commercialization program |
| May 14, 2026 | Anthropic × Gates Foundation | $200 million | Back artificial intelligence-related public goods and areas including health and education |
| May 19, 2026 | Incyte × Edison Scientific | Undisclosed | Use Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work |
| May 20, 2026 | Incyte × Genesis | Upfront consideration of $120 million + over $1 billion if all milestones are achieved | Expand collaboration to accelerate discovery of novel molecules for collaboration targets selected by Incyte |
| May 20, 2026 | Bristol Myers Squibb × Anthropic | Undisclosed | Make Claude available to over 30,000 employees to accelerate discovery, development and delivery of new medicines |
| May 20, 2026 | Collaborative Drug Discovery (CDD) × Eli Lilly | Undisclosed | Integrate Lilly TuneLab into CDD Vault |
| June 4, 2026 | Chai Discovery × Pfizer | Undisclosed | Use Chai's AI platform to help accelerate drug discovery and research |
| June 5, 2026 | Sanofi × Owkin | New deal terms not disclosed; extends a 2021 partnership worth about €90 million ($105.10 million) | Develop AI tools to support drug research and development |
| June 10, 2026 | Novartis × Orionis Biosciences | $40 mln upfront; up to $1.4 bln milestones + royalties | Discover and develop molecular glue medicines using Orionis' Allo-Glue platform |
| June 17, 2026 | Jazz Pharmaceuticals × AbCellera | $56 mln upfront; up to $792 mln in milestone payments | Discover next-generation T-cell engaging multispecific antibodies |
| July 1, 2026 | Takeda × Insilico Medicine | Up to $600 mln + tiered royalties | Use Insilico's AI platform to identify new drug candidates across Takeda's therapeutic areas |
| July 13, 2026 | Chai Discovery × Novartis | Undisclosed | Use Chai's AI platform to support antibody drug discovery across multiple targets |
| July 20, 2026 | Bristol Myers Squibb × NVIDIA | Undisclosed | Use Nvidia's AI computing system to help speed drug discovery and R&D |
| July 30, 2026 | GSK × Relation Therapeutics | Up to $110 mln, including upfront payment and success-based milestones | Generate large-scale human cell data and train AI models to support drug discovery |
| Aug. 5, 2026 | Schrödinger × Bristol Myers Squibb | Undisclosed | Deploy Schrödinger's AI research assistant Bunsen in Bristol Myers' drug discovery efforts |
| Aug. 20, 2026 | Bristol Myers Squibb BMY.N × Chai Discovery | Undisclosed | Use Chai's AI models and platform to support the discovery of therapeutic antibody candidates across Bristol Myers Squibb's pipeline |
XLV•
